Dear Friends and Colleagues

The European Hidradenitis Suppurativa Foundation (EHSF) holds its 8th Conference in Wroclaw, Poland. It is a great honour for us to guest outstanding clinicians and researches not only from European counties, but from all over the world. I am sure that the conference will promote all aspects of hidradenitis suppurativa research.

Wroclaw, lying on both banks of the Odra river, is a unique city with 12 islands and 112 bridges. As the main city of Lower Silesia it is the region’s economic, cultural and scientific capital. Wroclaw has been a place where various nationalities and numerous cultures meet. Nowadays it combines rich thousand-year history with modern life. Guests may see valuable architectural monuments, magic places, such as the Town Hall, Ostrów Tumski with the St. John Baptist Cathedral and Racławice Panorama – an extraordinary exhibition of the famous monumental painting of the battle. Moreover, visitors can find dozens of restaurants, cafes and pubs set in the historical beautiful center. In 2016 Wroclaw was the European Capital of Culture.

The 8th EHSF Conference in Wroclaw welcomes every contribution from those devoted to the progres of hidradenitis suppurativa research. It is our goal to have an international interdisciplinary meeting addressing physicians and scientists especially in dermatology and all other fields of related experimental medicine. I believe Wroclaw’s warm hospitality, pleasant atmosphere make our city the ideal place for this purpose. I do hope that besides the outstanding scientific program, participants will have opportunity to visit our city, enjoy social events and make new friendships.

I wish you a fruitful meeting and an unforgettable stay in Wroclaw.

On behalf of the Organizing Committee

Prof. Jacek C. Szepietowski, M.D. Ph.D.
Conference President
Dear Colleagues,

Participants of the 8th International EHSF Conference

The EHSF e.V. celebrates 13 years of fascinating work to be mirrored by your 120 submitted contributions, which summarize HS research and clinical activities on going around the globe. As EHSF e.V. president, I am impressed for what we have reached together. The huge developments in understanding HS pathophysiology and the needs of medical and psychological care of HS patients but also the targets for the years to come are the central subjects of the 8th International EHSF Conference. Parallelly, EHSF e.V. salutes all caring physicians and scientists, independently of their specialization, since the emerging HS comorbid disorders require an interdisciplinary approach.

There is a general consensus that it is difficult, even for experts, to follow the rapidly growing knowledge in the field. Therefore, I am honoured and pleased to welcome you together with our local hosts, Profs. Jacek C. Szepietowski and Łukasz Matusiak, at the 8th International EHSF Conference taking place at the traditional university city of Wroclaw. Our purpose was to construct a scientific programme of high impact providing current information on research and its clinical relevance on HS. The speakers have been selected among those of you, who submitted abstracts. Both experts in the field and motivated upcoming specialists are participating, but also young scientists and students working or wishing to work in this interesting field in the future and partners of the pharmaceutical industry. During the Conference you will have the opportunity to share your knowledge and perspectives and gain a better insight into HS. In addition to the fulfillment of your scientific expectations, I have no doubt that the 8th International EHSF Conference will become an unforgettable experience, especially since our local hosts have overtaken best efforts to satisfy your networking wishes and to present you Wroclaw and its warm-hearted people.

On behalf of the Organizing and Scientific Programme Committees

Prof. Dr. Prof. honoraire Dr. h.c. Christos C. Zouboulis
President of the EHSF e.V.
Organizing Committee

Jacek C. Szepietowski – Conference President
Łukasz Matusiak – Conference Vice-President
Edyta Lelonek – Conference Secretary General
Rafał Białynicki-Birula – Coordinate of USG Workshop
Staff Members of the Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland

Scientific Committee

Vincenzo Bettoli (Italy)
Veronique Del Marmol (Belgium)
Lennart Emtestam (Sweden)
Evangelos Giamarellos-Bourboulis (Greece)
Wayne Gulliver (Canada)
Gregor Jemec (Denmark)
Brian Kirby (Ireland)
Antonio Martorell-Calatayud (Spain)
Łukasz Matusiak (Poland)
Aude Nassif (France)
Errol Prens (The Netherlands)
Jacek C. Szepietowski (Poland)
Thrasyvoulos Tsillos (Norway)
Skaidra Valiukevičienė (Lithuania)
Hessel van der Zee (The Netherlands)
Christos C. Zouboulis (Germany)

Organizing Office

Symposium Cracoviense
ul. Krupnicza 3, 31-123 Kraków
Contact person: Agnieszka Bryk
phone: +48 666056444
e-mail: agnieszka.bryk@symposium.pl
General Information

The Registration Desk of the Conference will be in the lobby of Novotel Hotel, 7 Powstańców Śląskich Street, Wrocław.

- **Wednesday, 6 February 2019** 11 AM - 8 PM
- **Thursday, 7 February 2019** 8 AM - 6 PM
- **Friday, 8 February 2019** 8 AM - 6 PM

**Badges** should be worn during scientific and social events. You can be asked to show your badge for the entrance to the Opening Ceremony - Wroclaw Opera and Gala Dinner Africarium.

**Certificates** of attendance and invoices can be collected at the Conference Registration Desk.

**Poster Service** - Poster session will be located at London Room in dedicated place with number.

**Submission of Presentations** - The speakers are requested to submit their presentations in the Hall A and Hall B.

---

Conference Venue – Novotel Wrocław Centrum

7 Powstańców Śląskich Street, Wrocław

Novotel Wroclaw Centrum is located in the business centre of Wrocław and a short walk from the Old Town with its multiple tourist attractions. The modern design of the Novotel Wroclaw Centrum hotel gives its an extraordinary trendy atmosphere. Guests can enjoy delicious meals and relax after a long day in the fitness center or sauna. The hotel staff are very passionate about their work and aim to make your stay unforgettable. Its modern conference area makes it the ideal place for business meetings.
The Wrocław Opera

Wroclaw, 35 Świdnicka Street

WEDNESDAY 6TH OF FEBRUARY 2019
4.00 PM Opening Ceremony

The Wrocław Opera is one of the largest and most significant opera theatres in Poland. It was built in a classicistic style according the designs of architect Carl Ferdinand Langhans and opened in 1841 as the Breslau Opera. Extremely modern for its time, the theatre could hold an audience of up to 1600 spectators. Excluding break periods caused by fires in 1865 and 1871 the Wrocław Opera was actively present on the cultural map until 1944. During that time it became know as one of the leading German stages. After the Second World War the Wrocław Opera reassumed activity as a Polish theater. Stanisław Moniuszko’s “Halka”, which premiered on September 8th, 1945 marks the first performance shown to audiences after the war. Since then there were 11 premieres of this opera. Last one on the 14th and 15th of December 2018 marked the beginning of Moniuszko’s Year commemorating the 200th anniversary of the composer. The theater cooperates with famous producers and singers from all over the world. Its productions are recognized worldwide.
Africarium
Wroclaw, 1-5 Wróblewskiego Street, Vip Gate

THURSDAY 7TH OF FEBRUARY 2019

7.00 PM Gala Dinner
6.00 PM transfer from Novotel Hotel to Africarium

The Conference dinner during the 8th Conference of the European Hidradenitis Suppurativa Foundation will take place in Africarium, which is the first oceanarium in Poland and the only one in the world devoted to the flora and fauna of just one continent.

Africarium is a globally unique complex, depicting varied ecosystems related to an aquatic environment of the Dark Continent. The coral reef ecosystem was created in a reservoir with capacity of million liters of water, where one can admire over 60 species of beautiful and colourful fish.

Before refreshments we will stroll through the Africarium to observe: the common hippopotamus, remarkable aardvark frequently confused with South American giant anteater, colonies of naked mole-rat - extraordinary rodents, the aquaria with endemic fishes from lakes of the Great Rift Valley and the smallest antelope - dik-dik. We will marvel at green sea turtle, sharks, but also brown fur seal and African penguin. We will hope to catch a glimpse of jellyfishes, moray eels or quaint species of fish such as red lionfish. The reservoir is also inhabited by crocodiles and African manatee - uncanny, herbivorous mammal also known as a mermaid. Recently, all the species were joined by numerous birds.

It is a rare opportunity to host you in such an exquisite place. We truly welcome you to join us!
Download your event app, using one of the methods described below:
Scan this QR code to get your event app.

Use links to app stores to download your app.
Google Play (Android)
Apple AppStore (iOS)
https://itunes.apple.com/app/id773192307

WEDNESDAY 6\(^{\text{TH}}\) OF FEBRUARY 2019

HALL B

13:00-14:30  **USG Workshop**

**CHAIRS:** Antonio Martorell-Calatayud (Spain), Ximena Wortsman (Chile)

13:00-13:30  *Introducing the ultrasound in dermatology: re-discovering the hidradenitis suppurativa*

**Ximena Wortsman** (Santiago, Chile)

13:30-14:00  *Improving the medical management of hidradenitis suppurativa using ultrasound*

**Antonio Martorell-Calatayud** (Valencia, Spain)

14:00-14:30  *Role of ultrasound in the surgical management of hidradenitis suppurativa*

**Jorge Romani** (Barcelona, Spain)

* The practical trainings on USG in hidradenitis suppurativa will be offered to participants during next days of the Conference. Registration for practical trainings will be run at the Conference Registration Desk.
WEDNESDAY 6TH OF FEBRUARY 2019

15:15  transfer from Novolel Hotel to Wroclaw Opera

16:00-16:30  **Opening Ceremony**  
The Wroclaw Opera, 35 Świdnicka Street  

**Jacek C. Szepietowski** (Wroclaw, Poland) President of the Conference  
**Christos C. Zouboulis** (Dessau, Germany) President of EHSF

16:30-18:00  **Plenary Session**  
**CHAIRS:** Jacek C. Szepietowski (Poland), Christos C. Zoubulis (Germany), Gregor B.E. Jemec (Denmark)

16:30-17:00  *Misuse of psychoactive substances among patients with hidradenitis suppurativa*  
**Amit Garg** (New York, USA)

17:00-17:30  *Biomarkers of hidradenitis suppurativa/acne inversa*  
**Christos C. Zouboulis** (Dessau, Germany)

17:30-18:00  **Albert Neisser’s Lecture**  
*Updated Medical treatments of hidradenitis suppurativa, more options, less evidence*  
**Wayne Gulliver** (St. John’s, Canada)

19:00  **Welcome Reception in Foyer**
8:30-9:00  EHSF General Assembly

9:00-10:30  Genetics
CHAIRS: Evangelos Giamarellos-Bourboulis (Greece), Baoxi Wang (China)

9:00-9:15  Molecular profiling of hidradenitis suppurativa/acne inversa skin reveals immune related signatures influencing keratinocyte differentiation and innate immunity
André Nogueira da Costa (Brussels, Belgium)

9:15-9:30  DNA methylation and microRNA biomarkers for noninvasive detection of hidradenitis suppurativa
Uppala Radhakrishna (Royal Oak, USA)

9:30-9:45  In familial cases hidradenitis suppurativa occurs earlier and more severely in children than in parents
Philippe Guillem (Lyon, France)

9:45-10:00  In familial hidradenitis suppurativa, the gender of the parent who transmits the disease influences children’ phenotype
Philippe Guillem (Lyon, France)

10:00-10:15  MYH9: A newly identified mutation in 2 patients with steatocystoma multiplex suppurativa and their family members
Natalia Kirsten (Hamburg, Germany)

10:15-10:30  Discussion

10:30-11:00  COFFEE BREAK
11:00-12:30 **Immunology**  
**CHAIRS:** Errol Prens (The Netherlands), Aude Nassif (France)

11:00-11:15 *Hidradenitis suppurativa is an auto-inflammatory disease: results of an ex vivo study*  
**K.R. van Straalen** (Rotterdam, The Netherlands)

11:15-11:30 *The role of S100 proteins in hidradenitis suppurativa*  
**Aleksandra Batycka-Baran** (Wrocław, Poland)

11:30-11:45 *The IL-1 pathway is hyperactive in hidradenitis suppurativa and promotes skin infiltration and destruction*  
**Kerstin Wolk** (Berlin, Germany)

11:45-12:00 *MAIT cells in hidradenitis suppurativa: friend or foe?*  
**Catriona Gallagher** (Dublin, Ireland)

12:00-12:15 *Decreased serum level of interleukin-22 in patients with hidradenitis suppurativa*  
**Małgorzata Ponikowska** (Wrocław, Poland)

12:15-12:30 Discussion

12:30-14:00 **LUNCH BREAK**

14:00-15:30 **Epidemiology**  
**CHAIRS:** Veronique del Marmol (Belgium), Thrasyvoulos Tzellos (Norway)

14:00-14:15 *Hidradenitis suppurativa: disease burden on patients and the health care system in Germany – impact of severity and of duration of the disease*  
**Uwe Kirschner** (Mainz, Germany)

14:15-14:30 *The Lithuanian prospective study of patients with hidradenitis suppurativa based on clinical outcomes proposed by ERN-Skin*  
**Vesta Kucinskiene** (Kaunas, Lithuania)
14:30-14:45  *European Registry for hidradenitis suppurativa (ERHS): state of play 2018*
  **Mathilde Daxhelet** (Brussels, Belgium)

14:45-15:00  *Prevalence of hidradenitis suppurativa in German working population*
  **Natalia Kirsten** (Hamburg, Germany)

15:00-15:15  *A retrospective study of the characteristics of patients with early-onset hidradenitis suppurativa*
  **Philippe Guillem** (Lyon, France)

15:15-15:30  Discussion

15:30-16:00  **COFFEE BREAK**

16:00-17:30  **Medical Treatment 1**
  **CHAIRS:** Vincenzo Bettoli (Italy), Angelo Marzano (Italy)

16:00-16:15  *Intralvesional triamcinolone for fistulous tracts in hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up*
  **Jose C. Pascual** (Alicante, Spain)

16:15-16:30  *Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa - acne inversa in paediatric age: a prospective study*
  **Vincenzo Bettoli** (Ferrara, Italy)

16:30-16:45  *Antiandrogens as a therapeutic option for hidradenitis suppurativa/acne inversa*
  **Georgios Nikolakis** (Dessau, Germany)

16:45-17:00  *Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial*
  **Hessel van der Zee** (Rotterdam, The Netherlands)
17:00-17:15  *Addition of methotrexate to anti-TNF-a (infliximab or adalimumab) at induction treatment in severe hidradenitis suppurativa: improvement in therapeutic response and longer drug survival*
*Pierre-André Becherel* (Antony, France)

17:15-17:30  Discussion

---

**HALL B**

9:00-10:30  **Burden**
*CHAIRS:* Łukasz Matusiak (Poland), Arnon D. Cohen (Israel)

9:00-9:15  *High prevalence of psychological traumas in patients with hidradenitis suppurativa (HS)*
*Philippe Guillem* (Lyon, France)

9:15-9:30  *Indirect self-destructiveness in hidradenitis suppurativa patients*
*Amelia Głowaczewska* (Wrocław, Poland)

9:30-9:45  *Influence of proper diagnosis of hidradenitis suppurativa on patients daily life*
*Hans Bayer* (Freiburg, Germany)

9:45-10:00  *Sexual dysfunction in patients with hidradenitis suppurativa: prevalence and risk factors*
*Carlos Cuenca-Barrales* (Granada, Spain)

10:00-10:15  *Quality of life in hidradenitis suppurativa patients’ partners: preliminary results*
*Katarzyna Włodarek* (Wrocław, Poland)

10:15-10:30  Discussion

10:30-11:00  COFFEE BREAK
11:00-12:30  **Outcome Measures**  
**CHAIRS:** Hessel van der Zee (The Netherlands), Amit Garg (USA)

11:00-11:15  *A composite biomarker score for the diagnosis of hidradenitis suppurativa*  
**Evangelos Giamarellos-Bourboulis** (Athens, Greece)

11:15-11:30  *The initial development of HiSQOL: a hidradenitis suppurativa specific quality of life instrument*  
**Linnea Thorlacius** (Roskilde, Denmark)

11:30-11:45  *QoL-HS - disease specific assessment of life in hidradenitis suppurativa*  
**Natalia Kirsten** (Hamburg, Germany)

11:45-12:00  *Superscoring hidradenitis suppurativa*  
**Mathieu Daoud** (Brussels, Belgium)

12:00-12:15  *Assessment of reliability of six commonly used scoring systems for hidradenitis suppurativa in a group of dermatology residents*  
**Katarzyna Włodarek** (Wrocław, Poland)

12:15-12:30  Discussion

12:30-14:00  **LUNCH BREAK**

14:00-15:30  **Comorbidities**  
**CHAIRS:** Wayne Gulliver (Canada), Skaidra Valiukevičienė (Lithuania)

14:00-14:15  *Hidradenitis suppurativa comorbidities are similarly present in patients’ relatives and influence patients’ phenotype*  
**Philippe Guillem** (Lyon, France)

14:15-14:30  *High prevalence of metabolic syndrome in patients with hidradenitis suppurativa, hospital-based study*  
**Rositsa Lavcheva** (Stara Zagora, Bulgaria)
14:30-14:45  *Hidradenitis suppurative and ulcerative colitis, difficult treatment to control both pathologies at the same time*
*Veronica Monsalvez* (Madrid, Spain)

14:45-15:00  *Hidradenitis suppurativa and psychiatric disorders: the Florence experience*
*Francesca Prignano* (Florence, Italy)

15:00-15:15  *The treatment of hidradenitis suppurativa associated with SAPHO syndrome*
*Skaidra Valiukeviciene* (Kaunas, Lithuania)

15:15-15:30  Discussion

15:30-16:00  COFFEE BREAK

16:00-17:30  Program in Hall A
9:00-10:30  Medical Treatment 2  
**CHAIRS:** Christos C. Zouboulis (Germany), Jean Revuz (France)

9:00-9:15  Intensification strategies 80 mg weekly with adalimumab in hidradenitis suppurativa: when and what for?  
**Fernando Alfageme** (Majadahonda, Spain)

9:15-9:30  Efficacy of adalimumab in a patient with hidradenitis suppurativa and concomitant ulcerative colitis  
**Marisol Contreras-Steyls** (Malaga, Spain)

9:30-9:45  Effectiveness of secukinumab (anti-IL-17 monoclonal Ab) in hidradenitis suppurativa: an open study (17 cases)  
**Pierre-Andre Becherel** (Antony, France)

9:45-10:00  Hidradenitis suppurativa successfully treated with ixekizumab - presentation of 2 cases  
**Natalia Kirsten** (Hamburg, Germany)

10:00-10:15  Guselkumab in the treatment of severe hidradenitis suppurativa  
**Maximilian Kovacs** (Darmstadt, Germany)

10:15-10:30  Discussion

10:30-11:00  COFFEE BREAK

11:00-12:30  Abbvie Satellite Symposium  
**CHAIRS:** Afsaneh Alavi (USA), Falk Bechara (Germany), Hessel van der Zee (The Netherlands)
12:30-14:00  LUNCH BREAK

14:00-15:30  **Surgical Treatment**  
**CHAIRS:** Philippe Guillem (France), Andrzej Bieniek (Poland)

14:00-14:15  *Step by step surgery: a new therapeutic proposal for hidradenitis suppurativa*  
*Mariano Suppa* (Brussels, Belgium)

14:15-14:30  *Wide surgical excision as treatment modality for hidradenitis suppurativa: a retrospective cohort study*  
*Sree Ramu Suggu* (Chandigarh, India)

14:30-14:45  *Systematic review of complications and recurrences following surgical interventions in hidradenitis suppurativa*  
*Gregor Jemec* (Roskilde, Denmark)

14:45-15:15  *Rare forms and complex surgical situations in patients with HS*  
*Andrzej Bieniek & Falk Bechara* (Wroclaw, Poland & Bochum, Germany)

15:15-15:30  Discussion

15:30-16:00  COFFEE BREAK

16:00-17:30  **News from Clinical Trials**  
**CHAIRS:** Jacek C. Szepietowski (Poland), Gregor B.E. Jemec (Denmark)

16:00-16:15  *IFX-1 in patients with moderate to severe hidradenitis suppurativa/acne inversa (HS): baseline characteristics of a double-blind, randomized phase 2b dose-finding study (SHINE)*  
*Evangelos J Giamarellos-Bourboulis* (Athens, Greece)

16:15-16:30  *Long term results from a phase 2a clinical study with IFX-1 in severe hidradenitis suppurativa*  
*Evangelos J Giamarellos-Bourboulis* (Athens, Greece)
16:30-16:45  *Efficacy of adalimumab in moderate to severe hidradenitis suppurativa. Real life data*  
**Angeles Arnandis** (Valencie, Spain)

16:45-17:00  *The impact of hidradenitis suppurativa on absenteeism, reduced productivity, and work disability. Results from the PIRANHA study*  
**Sylke Schneider-Burrus** (Berlin, Germany)

17:00-17:15  *Impact of adalimumab on stabilization or sustained improvement in disease activity in moderate to severe hidradenitis suppurativa patients: an integrated analysis of PIONEER I and II trials through 36 weeks*  
**Alexa B Kimball** (Boston, USA)

17:15-17:30  Discussion

**17:30**  **Closing Ceremony**  
Jacek C. Szepietowski (Poland), Christos C. Zouboulis (Germany)
HALL B

9:00-10:30 **Innovative Research**
   **CHAIRS:** Brian Kirby (Ireland), Lennart Emtestam (Sweden)

9:00-9:15 *Deranged iron status in patients with hidradenitis suppurativa*
   **Małgorzata Ponikowska** (Wrocław, Poland)

9:15-9:30 *Serum Vitamin D in hidradenitis suppurativa patients: a pilot study*
   **Francesca Prignano** (Florence, Italy)

9:30-9:45 *Hidradenitis suppurativa in KID’s syndrome: genetic characterisation, clinical and surgical intervention*
   **Mayra Ianhez** (Goiania, Brasil)

9:45-10:00 Combined transcriptomic and immunohistochemical analysis of hidradenitis suppurativa lesions shows IL-17A pathway engagement
   **Christian Loesche** (Basel, Switzerland)

10:00-10:15 *Cutaneous manifestations of the STAT1 mutation*
   **Alba Sanchez Orta** (Madrid, Spain)

10:15-10:30 Discussion

10:30-11:00 **COFFEE BREAK**

11:00-12:30 **Program in Hall A**
12:30-14:00  LUNCH BREAK

14:00-15:30  Imaging
              **CHAIRS:** Antonio Martorell-Calatayud (Spain), Ximena Wortsman (Chile)

14:00-14:15  *Advances on ultrasound imaging of hidradenitis suppurativa*
              **Ximena Wortsman** (Santiago, Chile)

14:15-14:30  *Hidradenitis suppurativa phenotypes based on clinical and ultrasound characteristics*
              **Antonio Martorell-Calatayud** (Valencia, Spain)

14:30-14:45  *Color Doppler sonographic and epidemiological features of healing fistulous tracts in hidradenitis suppurativa patients treated with systemic and biological treatments*
              **Fernando Alfageme** (Majadahonda, Spain)

14:45-15:00  *Teleultrasonography for the early diagnosis of hidradenitis suppurativa in the primary cares setting*
              **Fernando Alfageme** (Majadahonda, Spain)

15:00-15:15  *Long-wave medical infrared thermography: a clinical biomarker of inflammation in hidradenitis suppurativa/acne inversa*
              **Christos C. Zouboulis** (Dessau, Germany)

15:15-15:30  Discussion

15:30-16:00  COFFEE BREAK

16:00-17:30  Program in Hall A
01 PS
*y-secretase mutation in etiology of acne inversa*
Beata Bergler-Czop, Katarzyna Sierant, Ligia Brzezińska-Wcisło (Katowice, Poland)

02 PS
*Hidradenitis Suppurativa/Dowling-Degos disease (DDD) phenotype associated with mutations in NCSTN gene*
Iris González-Villanueva, Inés Poveda Montoyo, Pedro Álvarez Chinchilla, María Gutiérrez, José Carlos Pascual Ramírez (Alicante, Spain)

03 PS
*Expression of Chitinase-3-like Protein 1 (YKL-40) in lesional and non-lesional skin of hidradenitis suppurativa*
Joanna Salomon, Aleksandra Piotrowska, Łukasz Matusiak, Piotr Dzięgiel, Jacek C. Szepietowski (Wrocław, Poland)

04 PS
*Novel anti-IL17 antibody (CJM112) reduces inflammation of hidradenitis suppurativa patients in a placebo-controlled trial*
Alexa Kimball (Boston, United States), Errol Prens (Rotterdam, The Netherlands), Falk G. Bechara (Bochum, Germany), Jamie Weisman (Atlanta, United States), Frank Kolbinger (Basel, Switzerland), Izabela Rozenberg (Basel, Switzerland), Julie Jones (Basel, Switzerland), Christian Loesche (Basel, Switzerland), Gregor B. Jemec (Roskilde, Denmark)

05 PS
*Serum levels of psoriasin (S100A7), calgranulin A (S100A8) and calgranulin B (S100A9) in patients suffering from hidradenitis suppurativa*
Aleksandra Batycka-Baran, Łukasz Matusiak, Danuta Nowicka-Suszko, Wojciech Baran, Jacek C. Szepietowski (Wrocław, Poland)
06 PS
*S100A4 and S100A15 as biomarkers of hidradenitis suppurativa disease activity with potential pathogenetic implications*
Aleksandra Batycka-Baran, Łukasz Matusiak, Danuta Nowicka-Suszko, Wojciech Baran, Jacek C. Szepietowski (Wrocław, Poland)

07 PS
*The aberrant expression of selected S100 proteins in skin lesions of patients suffering from hidradenitis suppurativa*
Aleksandra Batycka-Baran, Wojciech Baran, Maria Kozioł, Andrzej Bieniek, Łukasz Laczmanski, Jacek C. Szepietowski (Wrocław, Poland)

08 PS
*Brazilian consensus of hidradenitos suppurativa*
Renata Magalhaes (Campinas, Brazil), Maria Cecília Rivitti-Machado (São Paulo, Brazil), Gleison Duarte (Salvador, Brazil), Roberto Souto (Rio de Janeiro, Brazil), Mario Chaves (Rio de Janeiro, Brazil), Daniel Holthausen (Florianópolis, Brazil), Sergio Hirata (São Paulo, Brazil), Andrea Coelho (Belo Horizonte, Brazil)

09 PS
*Hidradenitis suppurativa: experience in Argentina’s reference center*
Alberto Jose Lavieri, Maria Florencia, Vera Morandini (Buenos Aires, Argentina)

10 PS
*Hidradenitis suppurativa: a single centre experience*
Aniza Giacaman, Oriol Corral-Magaña, Julián Boix-Vilanova, Daniel Ramos, Inés Gracia, Ana Martín-Santiago (Palma, Spain)

11 PS
*German consensus on documentation of hidradenitis suppurativa*
Natalia Kirsten, Katharina Herberger, Matthias Augustin, German Task force on Docu HS (Hamburg, Germany)

12 PS
*Hidradenitis suppurativa in the pediatric population: own experience*
Daria Wojtczyk, Amelia Glowaczewska, Jacek C. Szepietowski, Łukasz Matusiak (Wrocław, Poland)
13 PS
Which factors determine affected sites in hidradenitis suppurativa?
Farida BENHADOU (Brussels, Belgium), Axel VILLANI (Lyon, France), Philippe GUILLEM (Lyon, France)

14 PS
Alexander C. Katoulis (Athens Greece), Anastasia Trigoni (Thessaloniki, Greece), Elizabeth Lazaridou (Thessaloniki, Greece), Georgios Kontochristopoulos (Athens Greece), Aikaterini I. Liakou (Athens Greece), Elissavet Mingiani (Thessaloniki, Greece), Ourania Efthymiou (Athens Greece), Antigoni Alevizou (Athens Greece), Aikaterini Kyriakou (Thessaloniki, Greece), Evangelia Papadavid (Athens Greece), Dimitris Rigopoulos (Athens Greece)

15 PS
Hidradenitis suppurativa in a cohort of children and adolescents with overweight and obesity
Pernille Lindsø Andersen (Roskilde, Denmark), Charles Kromann (Roskilde, Denmark), Cilius Esmann Fonvig (Holbæk, Denmark), Peter Theut Riis (Roskilde, Denmark), Jens-Christian Holm (Holbæk, Denmark), Gregor Borut Jemec (Roskilde, Denmark)

16 PS
Demographic and biometric data of 1428 patients with hidradenitis suppurativa: EpiVer French multicenter study
Jean-Luc Perrot (St-Etienne, France), Anne Claire Fougerouse (St-Mandé, France), François Maccari (St-Mandé, France), Philippe Guillem (Ecculy, France), Nathalie Beneton (Le Mans, France), Raphaëlle Binois (Orleans, France), Charlotte Fite (Paris, France), Sarah Allal (St-Etienne, France), Elisa Cinotti (Siena, Italy)

17 PS
Personal and family history of 1428 subjects with hidradenitis suppurativa: EpiVer study
Jean-Luc Perrot (St-Etienne, France), Ziad Reguiai (Reims, France), Caroline Jacobzone (Lorient, France), Eic Tisserand (Clermont Ferrand, France), Eric Esteve (Orleans, France), Aude Nassif (Paris, France), Pierre Bravard (Montvillier, France), Anne Bénédicte Duval Modeste (Rouen, France), Nathalie Sultan (St Paul de la Réunion, France), Elisa Cinotti (Siena, Italy)
18 PS
*Evaluation of medical and surgical treatments for hidradenitis suppurativa from the Scandinavian registry (HISREG)*
Øystein Grimstad (Tromsø, Norway), Thrasyvoulos Tzellos (Harstad, Norway), Deirdre Nathalie Dufour (Kalundborg, Denmark), Øyvind Bremnes (Sortland, Norway), Inger Marie Skoie (Stavanger, Norway), Ingrid Snekvik (Trondheim, Norway), Elisabeth Jarnæss (Fornebu, Norway), Gislí Ingvarsson (Selfoss, Iceland)

19 PS
*Hidradenitis suppurativa: still unknown in primary care assistance*
Asunción Vicente Villa, Ana Talavera Belmonte, Emili Inarejos Clemente, Carolina Prat Torres, María Antonia González Enseñat (Esplugues, Spain)

20 PS
*Is subtyping of mammary HS lesions possible: a case series*
Rune Kjaersgaard Andersen (Roskilde, Denmark), Jurr Boer (Deventer, The Netherlands), Gregor B. E. Jemec (Roskilde, Denmark), Ditte Marie Saunte (Roskilde, Denmark)

21 PS
*Medical and surgical treatment of obesity*
Amita Barkat (Makkah, Saudi Arabia)

22 PS
*Frictional hidradenitis suppurativa induced by prostheses: an exogenous trigger?*
Ciara O’Grady, Fatima Awdeh, Anne Marie Tobin (Dublin, Ireland)

23 PS
*A case with fatal outcome due to squamous cell carcinoma over perineal hidradenitis suppurative*
Rosa Izu, Isabel Gainza, Mireya Lazaro, Begoña Ramos, Nerea Gonzalez-Romero, Ane Lobato (Bilboa, Spain)

24 PS
*Association of hidradenitis suppurativa and keloid formation: a therapeutic challenge*
Abdulhadi Jfri (Montreal, Canada), Elizabeth O’Brien (Montreal, Canada), Afsaneh Alavi (Toronto, Canada), Stephane Goldberg (Richmond, United States)
**25 PS**

*Association between hidradenitis suppurativa and myotonic dystrophy: a case report*
Saioa Oscoz-Jaime, Amaia Larumbe-Irurzun, Maialen Azcona Rodríguez, Iñigo Martínez de Espronceda-Ezquerro, Jone Sarriugarte-Aldecoa-Otalora, June Ignacio Yanguas-Bayona (Pamplona, Spain)

**26 PS**

*Is psoriasis a comorbidity of hidradenitis suppurativa?*
Rune Kjærsgaard Andersen, Sara Saunte, Gregor Jemec, Ditte Saunte (Roskilde, Denmark)

**27 PS**

*Is severity of hidradenitis suppurativa related to hypertension and angina pectoris? EpiVer study on 1428 subjects*
Jean-Luc Perrot (St-Etienne, France)

**28 PS**

*Ustekinumab with intravenous induction: results in hidradenitis suppurativa*
Jorge Romaní (Barcelona, Spain), Eva Vilarrasa (Barcelona, Spain), Antonio Martorell (Valencia, Spain), Irene Fuertes (Barcelona, Spain), Cristina Ciudad (Madrid, Spain), Alejandro Molina (Granada, Spain)

**29 PS**

*Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes*
Jose C.Pascual (Alicante, Spain), Luca.Schneller-Pavelescu (Alicante, Spain), Eduardo Vergara-de-Caso (Alicante, Spain), Antonio Martorell (Valencia, Spain), Jorge Romaní (Sabadell, Spain), Mireya Lázaro (Bilbao, Spain), Eva Vilarrasa (Barcelona, Spain), Blanca Díaz-Ley (Madrid, Spain), Igor Vázquez-Osorio (Gijón, Spain), Juan manuel Segura-Palacios (Marbella, Spain), Jose Manuel (Albacete, Spain), Marcos González-López (Santander, Spain), Javier Cañueto (Salamanca, Spain), Alejandro Molina-Leyva (Granada, Spain), María Leiva-Salinas (Alicante, Spain), Francisco J. Navarro-Triviño (Motril, Spain), José Sánchez-Payá (Alicante, Spain)

**30 PS**

*Effectivity and safety of adalimumab in hidradenitis suppurativa*
Jose Maria Ortiz Salvador, Jorge Magdaleno Tapial, Amparo Pérez Ferriols, Macarena Giacaman Von der Weth, Martina Saneleuterio Temporal, José Luis Sánchez Carazo (Valencia, Spain)
31 PS
Comparisons of disease status and symptom remission of hidradenitis suppurativa patients treated with biologics and non-biologics
Penny Robinson (Londyn, United Kingdom), Yao Lu (New York, United States), Rebecca Bergman (New York, United States), Peter Collins (Londyn, United Kingdom), Chitra Karki (New York, United States), Ipsos Mori (London, United Kingdom)

32 PS
Can hidradenitis suppurativa targeted antibiotic strategy improve Crohn disease symptoms?
Maïa Delage-Toriel, Thi Lam, Paul-Henri Consigny, Yoram Bouhnik, Laurent Beaugerie, Isabelle Nion-Larmurier, Philippe Seksik, Olivier Lortholary, Olivier Join-Lambert, Aude Nassif (Paris, France)

33 PS
Hidradenitis suppurativa and ankylosing spondylitis, resulting from secukinumab in the control of the two entities
Renata Magalhaes, Dimitri Silva, Andrea França (Campinas, Brazil)

34 PS
Biologics in hidradenitis suppurativa: where are we now?
Katarzyna Włodarek, Małgorzata Ponikowska, Łukasz Matusiak, Jacek C. Szepietowski (Wroclaw, Poland)

35 PS
The efficacy of modifying adalimumab 40mg weekly to adalimumab 80mg every two weeks for hidradenitis suppurativa; a multicenter retrospective cohort study
Julio Bassas-Vila, Eva Vilarrasa, Flavia Bittencourt (Barcelona, Spain)

36 PS
Therapeutic management of 1428 subjects suffering from hidradenitis suppurativa: EpiVer study
Jean-Luc Perrot (St-Etienne, France), Ziad Reguiai (Reims, France), Aude Nassif (Paris, France), Eric Esteve (Orleans, France), Eric Tisserand (Clermont Ferrand, France), Anne Benedicte Duval Modeste (Rouen, France), Pierre Bravard (Montvillier, France), Nathalie Sultan (St Paul de la Réunion, France), Elisa Cinotti (Siena, Italy), Caroline Jacobzone (Lorient, France), Pietro Rubegni (Siena, Italy)
37 PS
**Refractory inguinoscrotal suppurative hidradenitis successfully treated with surgery and adalimumab: the importance of the multidisciplinary approach**
Natalia Jiménez Gómez, Ander Aburto Bernardo, Pablo Benito Luque, Pedro Jaén Olasolo (Madrid, Spain)

38 PS
**Multidisciplinary committee for surgical management of hidradenitis suppurativa: our experience**
Patricia Garbayo (Sabadell, Spain), Jorge Roman (Sabadell, Spain), Albert Casulleras (Sabadell, Spain), Cristina Ferrer (Terrassa, Spain), Anna Pallisera (Sabadell, Spain), Jesús Luelmo (Sabadell, Spain)

39 PS
**Severe hidradenitis suppurativa in sacrum multidisciplinary approach**
Lucía Carnero, Itziar Arrue, Vanesa Fatsini, Amaia Saenz, Francisco de la Torre, Pau Roses, Ricardo González (Vitoria, Spain)

40 PS
**Efficacy and safety of biologic therapy in surgical management of hidradenitis suppurativa**
Virginia Sanz-Motilva (Manises, Spain), Alessandro Thione (Manises, Spain), Fatma Alkhawaja (Kuwait, Kuwait), Pilar Gómez-Palencia (Manises, Spain), Alberto Alfaro (Manises, Spain), Antonio Martorell (Manises, Spain)

41 PS
**Effectiveness, safety and tolerability of drainage and punch-trocar assisted cryoinsufflation (cryopunch) in the treatment of inflammatory acute fluid collections in hidradenitis suppurativa patients**
Luis Salvador-Rodriguez, Carlos Cuenca-Barrales, Antonio Martinez-Lopez, Alejandro Molina-Leyva (Granada, Spain)

42 PS
**Could be surgery helpful before treatment with adalimumab for severe hidradenitis?**
Blanca Díaz Ley, Guillermo Guhl, Maria Castellanos, Agustina Segurado (Madrid, Spain)
43 PS
Photodynamic therapy in the treatment of moderate-to-severe hidradenitis suppurativa: a report of 28 patients
Eva Vilarrasa (Barcelona, Spain), Flavia Bittencourt (Barcelona, Spain), Antonio Martorell (Valencia, Spain), Lluis Puig (Barcelona, Spain)

44 PS
VENUS Study: vision of hidradenitis suppurativa by family doctors in Portugal
Pedro Mendes-Bastos, Ana Brasileiro, Paulo Ferreira (Lisboa, Portugal)

45 PS
Influence of the duration of hidradenitis suppurativa on the quality of life and pain in 1428 subjects: EpiVer study
Jean-Luc Perrot (St-Etienne, France), Philippe Guillem (Ecculy, France), Francois Maccari (Saint-Mandé, France), Nathalie Beneton (Le Mans, France), Raphaëlle Binois (Orléans, France), Charlotte Fite (Paris, France), Sarah Allal (St-Etienne, France), Elisa Cinotti (Siena, Italy), Anne Claire Fougerouse (Saint-Mandé, France)

46 PS
Body mass index does not influence the quality of life and pain in 1428 subjects with hidradenitis suppurativa: EpiVer study
Jean-Luc Perrot (St-Etienne, France), Céline Girard (Montpellier, France), Philippe Guillem (Ecculy, France), François Skowron (Valence, France), Aude Nassif (Paris, France), Laure Mery Brossard (Mantes la Jolie, France), Pierre André Becherel (Antony, France), Sarah Allal (St-Etienne, France), (Siena, Italy)

47 PS
Is umbilical inflammation a sign of an impending hidradenitis suppurativa flare? A case series
Rune Kjærsgaard Andersen, Gregor BE Jemec, Ditte Marie Saunte (Roskilde, Denmark)

48 PS
A case of severe hidradenitis suppurativa successfully treated with secukinumab
Amelia Glowaczewska, Jacek C. Szepietowski, Lukasz Matusiak (Wroclaw, Poland)

49 PS
Staphylococcus aureus carriage status in patients with hidradenitis suppurativa
Alexander Katoulis, Vasiliki Koumaki, Dimitra Koumaki, Evangelia Dimitroulia, Maria Voudouri, Alexandra Voudouri, Athanasios Tsakris (Athens, Greece)
50 PS
*The microbiome of tunnels in hidradenitis suppurativa patients*
Hans Christian Ring, Viktoria Sigsgaard, Ditte Marie Saunte, Gregor Borut Jemec (Roskilde, Denmark)

51 PS
*3D-SeboSkin model for human ex vivo studies of hidradenitis suppurativa/acne inversa*
Xiaoxiao Hou, Amir M Hossini, Georgios Nikolakis, Christos C. Zouboulis (Dessau, Germany)

52 PS
*Upregulation of SERPINB3/B4 and S100A7-9 in hidradenitis suppurativa/acne inversa*
Daifallah Almansouril, Christos C. Zouboulis (Dessau, Germany)

53 PS
*Impact of adalimumab treatment on 30 patients’ quality of life*
Georgios Kontochristopoulos, Aikaterini I. Liakou, Ioannis Marnelakis, Antigoni Alevizou, Stavros Sianos, Efthymia Agiasofitou, Nikolaos Rotsiamis, Dimitris Rigopoulos (Athens, Greece)

54 PS
*Prevalence and associated factors of alexithymia in patients with hidradenitis suppurativa*
Amelia Glowaczewska, Jacek C. Szepietowski, Łukasz Matusiak (Wroclaw, Poland)

55 PS
*The burden of teledermatological treatment of hidradenitis suppurativa in the Faroe Islands*
Rune Kjærsgaard Andersen, Gregor Jemec (Roskilde, Denmark)

56 PS
*Itch and pain influence on sleep in hidradenitis suppurativa patients: comparison to other chronic dermatoses*
Karolina Kaaz, Łukasz Matusiak, Jacek C. Szepietowski (Wroclaw, Poland)

57 PS
*Clinical and epidemiological features associated with pruritus and bad odor in patients with hidradenitis suppurativa*
Alejandro Molina-Leyva, Carlos Cuenca-Barrales (Granada, Spain)
Gold Sponsor:

Abbvie
26525 N. Riverwoods Blvd, Mettawa IL 60045, USA
www.abbvie.com

Silver Sponsor:

Novartis Pharma AG
Novartis Campus
CH-4002 Basel, Switzerland
www.novartis.com

Bronze Sponsor:

InflaRx N.V.
Winzerlaer Str. 2
07745 Jena, Germany
www.inflarx.de

Partner:

Mylan Healthcare Sp. z o. o.
ul. Postępu 21B
02-676 Warszawa, Poland
www.mylan.com.pl
Conference Venue Floor Plan

1. Hall A (Warszawa Room + Praga Room)
2. Hall B (Berlin Room)
3. Posters (Londyn Room + Paryż Room)
4. EHSF Speakers’ Room (Rzym Room)
5. Conference Registration
<table>
<thead>
<tr>
<th>Time</th>
<th>Wednesday 6th of February</th>
<th>Thursday 7th of February</th>
<th>Friday 8th of February</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.00 AM</td>
<td>Opening Ceremony</td>
<td>EHSF General Assembly</td>
<td>7.00 AM</td>
</tr>
<tr>
<td>7.30 AM</td>
<td>USG Workshop</td>
<td>Genetics</td>
<td>7.30 AM</td>
</tr>
<tr>
<td>8.00 AM</td>
<td>Plenary Session</td>
<td>Burden</td>
<td>8.00 AM</td>
</tr>
<tr>
<td>8.30 AM</td>
<td></td>
<td>Medical Treatment 1</td>
<td>8.30 AM</td>
</tr>
<tr>
<td>9.00 AM</td>
<td></td>
<td>Medical Treatment 2</td>
<td>9.00 AM</td>
</tr>
<tr>
<td>9.30 AM</td>
<td></td>
<td>Innovative Research</td>
<td>9.30 AM</td>
</tr>
<tr>
<td>10.00 AM</td>
<td>COFFEE BREAK</td>
<td></td>
<td>10.00 AM</td>
</tr>
<tr>
<td>10.30 AM</td>
<td>Immunology</td>
<td>COFFEE BREAK</td>
<td>10.30 AM</td>
</tr>
<tr>
<td>11.00 AM</td>
<td></td>
<td>Abbvie Satellite Symposium</td>
<td>11.00 AM</td>
</tr>
<tr>
<td>11.30 AM</td>
<td>LUNCH BREAK</td>
<td></td>
<td>11.30 AM</td>
</tr>
<tr>
<td>12.00 PM</td>
<td></td>
<td>LUNCH BREAK</td>
<td>12.00 PM</td>
</tr>
<tr>
<td>12.30 PM</td>
<td></td>
<td>Medical Treatment 2</td>
<td>12.30 PM</td>
</tr>
<tr>
<td>1.00 PM</td>
<td></td>
<td>COFFEE BREAK</td>
<td>1.00 PM</td>
</tr>
<tr>
<td>1.30 PM</td>
<td></td>
<td>Abbvie Satellite Symposium</td>
<td>1.30 PM</td>
</tr>
<tr>
<td>2.00 PM</td>
<td></td>
<td>Surgical Treatment</td>
<td>2.00 PM</td>
</tr>
<tr>
<td>2.30 PM</td>
<td></td>
<td>COFFEE BREAK</td>
<td>2.30 PM</td>
</tr>
<tr>
<td>3.00 PM</td>
<td></td>
<td>Imaging</td>
<td>3.00 PM</td>
</tr>
<tr>
<td>3.30 PM</td>
<td></td>
<td>COFFEE BREAK</td>
<td>3.30 PM</td>
</tr>
<tr>
<td>4.00 PM</td>
<td></td>
<td>News from Clinical Trials</td>
<td>4.00 PM</td>
</tr>
<tr>
<td>4.30 PM</td>
<td></td>
<td>Closing Ceremony</td>
<td>4.30 PM</td>
</tr>
<tr>
<td>5.00 PM</td>
<td></td>
<td></td>
<td>5.00 PM</td>
</tr>
<tr>
<td>5.30 PM</td>
<td></td>
<td></td>
<td>5.30 PM</td>
</tr>
<tr>
<td>6.00 PM</td>
<td></td>
<td></td>
<td>6.00 PM</td>
</tr>
<tr>
<td>6.30 PM</td>
<td></td>
<td></td>
<td>6.30 PM</td>
</tr>
<tr>
<td>7.00 PM</td>
<td>Welcome Reception</td>
<td></td>
<td>7.00 PM</td>
</tr>
<tr>
<td>7.30 PM</td>
<td></td>
<td></td>
<td>7.30 PM</td>
</tr>
<tr>
<td>8.00 PM</td>
<td></td>
<td></td>
<td>8.00 PM</td>
</tr>
</tbody>
</table>